2025 WCLC Meeting
At the 2025 WCLC, Wayshine Biopharm announced the latest data from the Phase I/II clinical study of its fourth-genera Release time：2025-12-10
2025 SNO Meeting
At the 2025 SNO Annual Meeting, Wayshine Biopharm presented data from the Brain Penetrable Cohort of the clinical tri Release time：2025-10-10
2023 SNO Meeting
At the 2023 SNO Annual Meeting, Wayshine Biopharm presented the latest data on its fourth-generation EGFR inhibitor, Release time：2023-12-15
2023 ASCO Meeting At the 2023 ASCO Annual Meeting, Wayshine Biopharm presented the preliminary results from the dose-escalation phase of t Release time：2023-12-10
2022 AACR Meeting
Wayshine Biopharm attended AACR 2022 in New Orleans, and associated with Mayo Clinic to present the poster with impr Release time：2022-04-18
